Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,203.48

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,185.20 15
Travel and Lodging $1,018.28 4

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1508866443?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $2,203.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $98.1712/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647898683 CMS
Novartis Pharmaceuticals Corporation $13.2411/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659675431 CMS
Lilly USA, LLC $18.5411/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658089165 CMS
AbbVie, Inc. $7.5510/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647898677 CMS
Sun Pharmaceutical Industries Inc. $23.2510/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704606843 CMS
AbbVie, Inc. $109.2009/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647898681 CMS
UCB, Inc. $16.7908/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688320283 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.7508/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684578905 CMS
Regeneron Healthcare Solutions, Inc. $25.1907/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673382809 CMS
Regeneron Healthcare Solutions, Inc. $23.7206/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673382807 CMS
PFIZER INC. $82.2005/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672470117 CMS
AbbVie, Inc. $115.0005/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647898679 CMS
STRATA Skin Sciences, Inc. $2.4504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668579351 CMS
PFIZER INC. $243.2104/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672460055 CMS
PFIZER INC. $596.9704/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672460361 CMS
PFIZER INC. $182.7704/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672460365 CMS
PFIZER INC. $510.1004/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672460369 CMS
Sun Pharmaceutical Industries Inc. $104.3501/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704606845 CMS
Allergan Inc. $11.0301/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670406167 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,600.00 11/25/2022 Non-covered Recipient Entity
Dundee Dermatology
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 933186453
Principal investigator 1 PFIZER INC. $5,122.00 11/15/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949731685
Principal investigator 1 ABBVIE INC. $3,560.60 11/09/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889819639
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,859.13 11/04/2022 Covered Recipient Teaching Hospital
Swedish Medical Center
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 933188333
Principal investigator 1 PFIZER INC. $8,104.20 09/24/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949732523
Principal investigator 1 PFIZER INC. $2,561.00 09/22/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949742777
Principal investigator 1 PFIZER INC. $2,561.00 08/23/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949733461
Principal investigator 1 PFIZER INC. $3,270.80 08/23/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949736961
Principal investigator 1 PFIZER INC. $1,635.40 08/16/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949742393
Principal investigator 1 ABBVIE INC. $7,834.25 07/14/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889800973
Principal investigator 1 PFIZER INC. $2,561.00 07/08/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735039
Principal investigator 1 PFIZER INC. $6,485.35 06/25/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949743703
Principal investigator 1 PFIZER INC. $2,561.00 06/24/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949742933
Principal investigator 1 ABBVIE INC. $2,012.00 06/08/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889794009
Principal investigator 1 PFIZER INC. $97.50 06/02/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949733911
Principal investigator 1 PFIZER INC. $1,635.40 05/07/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949737803
Principal investigator 1 PFIZER INC. $1,635.40 04/26/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949734381
Principal investigator 1 PFIZER INC. $5,122.00 03/23/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949735111
Principal investigator 1 Novartis Pharmaceuticals Corporation $459.72 03/08/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EXTENSION STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE LONG-TERM EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 909396183
Principal investigator 1 PFIZER INC. $3,270.80 03/01/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949731599
Principal investigator 1 ABBVIE INC. $3,154.00 02/22/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) No dispute reported 06/30/2026 889778227
Principal investigator 1 Eli Lilly and Company $8,375.00 02/16/2022 Non-covered Recipient Entity
PAUL GETZ MD SC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917829767
Principal investigator 1 Amgen Inc. $7,135.05 02/14/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Interchangeability Study ABP 654 No dispute reported 06/30/2026 942841487
Principal investigator 1 PFIZER INC. $5,122.00 02/04/2022 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949734802
Principal investigator 1 PFIZER INC. $1,635.40 02/03/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949736903
Principal investigator 1 Eli Lilly and Company $7,263.00 02/02/2022 Non-covered Recipient Entity
PAUL GETZ MD SC
A PHASE 3, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO ASSESS THE IMPACT OF LEBRIKIZUMAB ON VACCINE RESPONSES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 917837889
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,637.36 01/25/2022 Non-covered Recipient Entity
PAUL GETZ MD SC DUNDEE DERMATOLOGY
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 909412891
Principal investigator 1 Amgen Inc. $32,064.96 01/24/2022 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Interchangeability Study ABP 654 No dispute reported 06/30/2026 942841489
Principal investigator 1 PFIZER INC. $3,270.80 01/08/2022 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 949736968